ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public OfferingIRVINE, Calif., Feb. 15, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (“ReShape” or the “Company”) (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its public offering of 2,575,107 units at a public offering price of $2.33 per unit. Each unit consists of one common share (or pre-funded warrant to purchase one common share in-lieu thereof) and one warrant to purchase one common share.
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate UpdateRevenue Increased 16.6% in the Third Quarter of 2024 Over the Second Quarter, Representing the Third Sequential Quarter of Growth, and 6.4% Compared to the Same Period in 2023
ReShape Lifesciences Announces 1-for-58 Reverse Stock SplitEffective as of Commencement of Trading on September 23, 2024
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad MedisysReShape and Vyome, a Clinical Stage Specialty Pharmaceutical Company Working To Treat Immuno-Inflammatory Diseases of Unmet Need, to Combine in All-Stock Merger
ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership AlternativesIRVINE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it has engaged Maxim Group LLC, to act as the Company’s exclusive financial advisor to identify potential strategic merger and acquisition partnership alternatives. The Company does not have a defined timeline for such a transaction and cannot provide any assurance whether or when any transaction will be announced or consummated.
ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross ProceedsIRVINE, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences, Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, announced today that it has entered into a warrant exercise agreement with an existing accredited investor to exercise outstanding warrants to purchase an aggregate of 5,382,500 shares of the company’s common stock. In consideration for the immediate exercise of the existing warrants for cash, the exercising holder received new unregistered warrants to purchase up to an aggregate of 10,765,000 shares (equal to 200% of the shares of common stock issued in connection with the exercise) of the company’s common stock. In connection with the exercise, the company also agreed to reduce the exercise price of the 5,382,500 exercised warrants and 6,960,351 remaining unexercised warrants to $0.23, which is equal to the most recent closing price of the company’s common stock on The Nasdaq Capital Market prior to the execution of the warrant exercise agreement.
ReShape Lifesciences® Announces Pricing of $3.0 Million Public OfferingIRVINE, Calif., Sept. 29, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its public offering of 9,100,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant to purchase one share of common stock in lieu thereof), and warrants to purchase one and one half shares of common stock. Each unit is being sold at a public offering price of $0.33. The warrants will be immediately exercisable at a price of $0.33 per share, subject to reduction as set forth in the warrants, and will expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance.
ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVIIRVINE, Calif., Sept. 22, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul F. Hickey, President and Chief Executive Officer, and Tom Stankovich, Chief Financial Officer, will present a company overview on Tuesday, October 3, 2023 at 3:30 PM PT, at LD Micro’s 16th Annual Main Event, taking place October 3-5 at the Luxe Sunset Boulevard Hotel in Los Angeles. During the presentation, management will highlight the company’s next-generation, anatomy-sparing, Lap-Band® program and the nationwide, ReShapeCare™ virtual weight-management program.
ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon SystemRoyalty-Bearing License Agreement Covers the Countries in the Indian Subcontinent, Representing Approximately 20% to 25% of the World’s Population
ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon SystemGranted One Patent from USPTO and Receives Two Notices of Allowance, Providing Foundational Protection
ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device$331,541 Grant will Explore the use of High-Resolution Endoscopic Ultrasound to Aid in the Placement of the DBSN™ Device
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2023 Financial Results and Provides Corporate UpdateCompany Executing Its Plan for Growth; Achieves Continued Improvement in Operational Effectiveness Reducing Second Quarter Operating Expenses by 53% Compared to Second Quarter of 2022
ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization SoftwareHive’s AI- and SMS-based Patient-Self-Service Technology to Manage Prospective Lap-Band® Leads From Initial Contact Through Surgical Consultation
ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual MeetingIRVINE, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today presented data on its proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device in an e-poster at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2023 Annual Meeting, being held in Las Vegas, NV, June 25 - 29, 2023.
ReShape Lifesciences® to Participate in Investor and Industry Conferences in JuneSAN CLEMENTE, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced participation in the following investor and industry conferences in June:
ReShape Lifesciences® Reports First Quarter Ended March 31, 2023 Financial Results and Provides Corporate UpdateAchieved Continued Improvement in Operational Effectiveness With First Quarter 2023 Operating Expenses Down 42.9% Compared to the First Quarter of 2022
ReShape Lifesciences® to Present Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the Keystone Symposia on Type 2 DiabetesSAN CLEMENTE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will present data on its proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device in a poster at the Keystone Symposia on Type 2 Diabetes: Understanding its Early Drivers and the Road to Therapeutics, being held in Palm Springs, CA, May 1 – 4, 2023.
ReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-MarketSAN CLEMENTE, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 800,695 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 800,695 shares of common stock. The combined effective offering price for each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrant is $3.07. The warrants will be immediately exercisable, will expire five and a half years from the issuance date and will have an exercise price of $3.07 per share.
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon SystemSAN CLEMENTE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/792,094, entitled, “Systems and Methods for Determining Failure of Intragastric Devices,” related to its Obalon® Balloon System. The patent will cover additional claims for the Obalon® Balloon System and is expected to provide protection into at least January 2031, without accounting for a potential Patent Term Extension (PTE).
ReShape Lifesciences® To Delay Year Ended December 31, 2022 Earnings Release and Conference CallSAN CLEMENTE, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will delay its year ended December 31, 2022 earnings release and conference call, previously scheduled for 8:00 am ET on March 29, 2022. The delay is required to allow the company additional time to complete its year end audited financial information.
ReShape Lifesciences Announces Formation of International Scientific Advisory BoardTop Industry Experts in Bariatric Surgery and Obesity Will Help Solidify ReShape’s Position as the Premier Physician-Led Weight Loss and Metabolic Health Solutions Company
ReShape Lifesciences® to Present at the Q2 Virtual Investor SummitSAN CLEMENTE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul F. Hickey, President and Chief Executive Officer, and Tom Stankovich, Chief Financial Officer, will present a company overview at the Q2 Virtual Investor Summit on Wednesday, March 29 at 1:00 pm ET. During the virtual presentation, management will highlight the Company’s three pillars for growth and its portfolio of products that address the entire weight loss continuum including the anatomy-sparing Lap-Band®.
ReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public OfferingSAN CLEMENTE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the closing of its upsized underwritten public offering of 1,275,000 units, with each unit consisting of one share of its common stock, or one pre-funded warrant to purchase one share of its common stock, and one warrant to purchase one and one-half shares of its common stock. Each unit was sold at a public offering price of $8.00. The warrants in the units are immediately exercisable at a price of $8.00 per share and expire five years from the date of issuance. Alternatively, each warrant will become exercisable for 0.75 shares of common stock under the cashless exercise provision included in the common warrants rather than the 1.5 shares of common stock under the cash exercise provision. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants were only purchasable together in this offering, but were issued separately and immediately separable upon issuance.
ReShape Lifesciences Announces Pricing of Upsized $10.2 Million Underwritten Public OfferingSAN CLEMENTE, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its upsized underwritten public offering of 1,275,000 units, with each unit consisting of one share of its common stock, or one pre-funded warrant to purchase one share of its common stock, and one warrant to purchase one and one-half shares of its common stock. Each unit is being sold at a public offering price of $8.00. The warrants in the units will be immediately exercisable at a price of $8.00 per share and will expire five years from the date of issuance. Alternatively, each warrant will become exercisable for 0.75 shares of common stock under the cashless exercise provision included in the common warrants rather than the 1.5 shares of common stock under the cash exercise provision. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance.
ReShape Lifesciences Announces 1-for-50 Reverse Stock Split Effective as of Commencement of Trading on December 23, 2022SAN CLEMENTE, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has declared a 1-for-50 reverse stock split of the company’s common stock, which will be effective for trading purposes upon the commencement of trading on December 23, 2022. At that time, each 50 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. As a result of the reverse stock split, proportional adjustments will be made to the number of shares of common stock issuable upon exercise or conversion, and the per share exercise or conversion price of the company’s outstanding warrants, stock options and convertible preferred stock, in each case in accordance with their terms. Any fractional shares of common stock resulting from the reverse stock split will be rounded up to the nearest whole share. In connection with the reverse stock split, the company also increased the number of shares of common stock that it is authorized to issue under its certificate of incorporation to 300 million shares. The number of authorized shares of common stock and preferred stock under the company’s certificate of incorporation will not be reduced in connection with the reverse stock split.
ReShape Lifesciences Announces $750,000 Registered Direct OfferingSAN CLEMENTE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale in a registered direct offering of 2,884,615 shares of the Company’s common stock (or common stock equivalents in the form of pre-funded warrants) at a purchase price of $0.26 per share and 2,500 shares of series D mirroring preferred stock (“Series D Preferred Stock”) and, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 2,884,615 shares of common stock. Each share of Series D Preferred Stock has a stated value of $0.001 per share and will automatically terminate on the date that the Company effects a reverse stock split of the Company’s shares of common stock or, if later, the date the Company effects an increase in its authorized shares of common stock. The warrants have an exercise price of $0.30 per share, will become exercisable six months following the date of issuance and will expire five and one-half years following the date of issuance. The closing of the offering is expected to occur on or about November 9, 2022, subject to the satisfaction of customary closing conditions.
ReShape Lifesciences™ Presents Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at ObesityWeek®Stimulation of Vagus Celiac Fibers with Concurrent High Frequency Alternating Current Block of Hepatic Fibers Decreases Glucose Variability in a Swine Model of Type 2 Diabetes
ReShape Lifesciences to Present at the Q4 Investor SummitSAN CLEMENTE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul F. Hickey, President and Chief Executive Officer, and Tom Stankovich, Chief Financial Officer, will present a company overview at the Q4 Investor Summit on Monday, November 14 at 1:30 p.m. ET. During the presentation, management will highlight its next-generation, anatomy-sparing, Lap-Band® program and the nationwide, reshapecare™ virtual health coaching program.
ReShape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band®Lap-Band® is the Only FDA Approved Device Indicated for Weight Reduction in Patients With a Body Mass Index (BMI) of at Least 40 kg/m2 or a BMI of at least 30 kg/m2 With One or More Obesity-Related Comorbidities
ReShape Lifesciences Announces Appointment of Paul F. Hickey as President and Chief Executive OfficerSAN CLEMENTE, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has appointed Paul F. Hickey as President and Chief Executive Officer and as a member of the Board of Directors, effective August 15, 2022. Mr. Hickey succeeds Bart Bandy, who has separated from the company to pursue other opportunities. Thomas Stankovich, Chief Financial Officer of ReShape, will serve as Interim President and Chief Executive Officer until Mr. Hickey joins the company. Dan W. Gladney, current Chair of the Board of Directors, will assume a more active role as Executive Chair, supporting Mr. Hickey and the company on strategic matters.
